Beigene Ltd (NASDAQ:BGNE)
| 184.82 Delayed Data As of Nov 28 |  +1.88 / +1.03%Today’s Change | 156.56 Today|||52-Week Range 280.62 | -15.97% Year-to-Date |
Latest BGNE News | Press Releases
| The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics Nov 21 / Zacks.com - Paid Partner Content | 5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024 Nov 20 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 182.96 |
| Today’s open | 181.60 |
| Day’s range | 181.28 - 185.00 |
| Volume | 104,101 |
| Average volume (3 months) | 223,235 |
| Market cap | -- |
Data as of 3:59pm ET, 11/28/2023
Growth & Valuation
| Earnings growth (last year) | -27.55% |
| Earnings growth (this year) | +36.40% |
| Earnings growth (next 5 years) | -39.43% |
| Revenue growth (last year) | +20.37% |
| P/E ratio | NM |
| Price/Sales | 16.02 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TEVATeva Pharmaceutical | +0.00 | +0.05% |
| BBIOBridgeBio Pharma Inc | -0.95 | -3.19% |
| IDRSFIdorsia Ltd | 0.00 | 0.00% |
| ---- |
Data as of 4:00pm ET, 11/28/2023
Financials
| Next reporting date | March 27, 2024 |
| EPS forecast (this quarter) | -$3.12 |
| Annual revenue (last year) | $1.4B |
| Annual profit (last year) | -$2.0B |
| Net profit margin | -141.52% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters George Town, George Town |
Forecasts
